To confirm the role of IFN in limiting the replication of the NS1 revertant viruses, we treated equine cells 24 h prior to infection (MOI, 0.1) with ruxolitinib (Selleck Chemicals) to block the JAK/STAT pathway and thus impaired the ability of the cells to respond to IFN (25). Here, IFNA1 is linked to infection.